PL2079443T3 - Podwójne działanie, wziewne formulacje zapewniające zarówno natychmiastowy jak i przedłużony profil uwalniania - Google Patents

Podwójne działanie, wziewne formulacje zapewniające zarówno natychmiastowy jak i przedłużony profil uwalniania

Info

Publication number
PL2079443T3
PL2079443T3 PL07867260T PL07867260T PL2079443T3 PL 2079443 T3 PL2079443 T3 PL 2079443T3 PL 07867260 T PL07867260 T PL 07867260T PL 07867260 T PL07867260 T PL 07867260T PL 2079443 T3 PL2079443 T3 PL 2079443T3
Authority
PL
Poland
Prior art keywords
immediate
sustained release
release profile
dual action
formulations providing
Prior art date
Application number
PL07867260T
Other languages
English (en)
Inventor
David C Cipolla
James Blanchard
Original Assignee
Aradigm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aradigm Corp filed Critical Aradigm Corp
Publication of PL2079443T3 publication Critical patent/PL2079443T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07867260T 2006-10-24 2007-10-23 Podwójne działanie, wziewne formulacje zapewniające zarówno natychmiastowy jak i przedłużony profil uwalniania PL2079443T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86275306P 2006-10-24 2006-10-24
PCT/US2007/022424 WO2008063341A2 (en) 2006-10-24 2007-10-23 Dual action, inhaled formulations providing both an immediate and sustained release profile
EP07867260.7A EP2079443B1 (en) 2006-10-24 2007-10-23 Dual action, inhaled formulations providing both an immediate and sustained release profile

Publications (1)

Publication Number Publication Date
PL2079443T3 true PL2079443T3 (pl) 2015-02-27

Family

ID=39430258

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07867260T PL2079443T3 (pl) 2006-10-24 2007-10-23 Podwójne działanie, wziewne formulacje zapewniające zarówno natychmiastowy jak i przedłużony profil uwalniania

Country Status (12)

Country Link
US (2) US8268347B1 (pl)
EP (3) EP2789330A1 (pl)
JP (2) JP5254239B2 (pl)
CN (2) CN104666248B (pl)
AU (1) AU2007322224B2 (pl)
CA (1) CA2667494C (pl)
DK (1) DK2079443T3 (pl)
ES (1) ES2520028T3 (pl)
PL (1) PL2079443T3 (pl)
PT (1) PT2079443E (pl)
SI (1) SI2079443T1 (pl)
WO (1) WO2008063341A2 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US8226975B2 (en) 2005-12-08 2012-07-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
WO2007117550A2 (en) * 2006-04-06 2007-10-18 Transave, Inc. Methods for coacervation induced liposomal encapsulation and formulations thereof
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
WO2009091531A2 (en) * 2008-01-16 2009-07-23 The General Hospital Corporation Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
TW201010708A (en) * 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
AU2009302042A1 (en) 2008-10-07 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomal systems comprising sphingomyelin
JP2013515079A (ja) * 2009-12-22 2013-05-02 カロバイオス ファーマシューティカルズ インコーポレイティッド 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法
EP2544663B1 (en) 2010-03-12 2018-01-03 Berg LLC Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
CN102309448B (zh) * 2010-06-29 2014-07-09 中国人民解放军军事医学科学院毒物药物研究所 一种肺部给药的环丙沙星药用组合物及其制备方法
US10610486B2 (en) * 2010-10-28 2020-04-07 Pacira Pharmaceuticals, Inc. Sustained release formulation of a non-steroidal anti-inflammatory drug
IT1405998B1 (it) * 2010-12-09 2014-02-06 Bionest Ltd Gel polifunzionale contro la secchezza vaginale ad effetto diretto e ritardato
EA201490047A1 (ru) * 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
WO2013057208A1 (en) * 2011-10-18 2013-04-25 Targeted Delivery Technologies Limited Compositions and methods for reducing the proliferation and viability of microbial agents
EP2780467B1 (en) 2011-11-14 2018-10-17 Alfasigma S.p.A. Assays and methods for selecting a treatment regimen for a subject with depression and methods for treatment
JP6402097B2 (ja) 2012-05-21 2018-10-10 インスメッド インコーポレイテッド 肺感染症を処置するためのシステム
WO2014058974A1 (en) * 2012-10-10 2014-04-17 Emory University Methods of managing inflammation using glycolysis pathway inhibitors
ES2743039T3 (es) 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
WO2015061025A1 (en) 2013-10-22 2015-04-30 Aradigm Corporation Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
US9968555B2 (en) 2014-04-08 2018-05-15 Aradigm Corporation Liposomal formulations that form drug nanocrystals after freeze-thaw
AU2015244275B2 (en) * 2014-04-08 2019-08-29 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
SI3142643T1 (sl) 2014-05-15 2019-11-29 Insmed Inc Postopki za zdravljenje pljučnih netuberkuloznih mikobakterijskih infekcij
US10765817B2 (en) 2014-08-13 2020-09-08 Elwha, Llc Methods, systems, and devices related to delivery of alcohol with an inhaler
US10987048B2 (en) 2014-08-13 2021-04-27 Elwha Llc Systems, methods, and devices to incentivize inhaler use
US10245393B2 (en) 2014-08-13 2019-04-02 Elwha Llc Methods, systems, and devices related to a supplemental inhaler
WO2016179365A1 (en) * 2015-05-05 2016-11-10 Musc Foundation For Research Development Nanocarriers for delivery of alpha-1-antitrypsin
TWI609701B (zh) 2016-01-05 2018-01-01 國立交通大學 滴點式複合藥物凝膠及其製備方法
US20170355933A1 (en) * 2016-06-09 2017-12-14 The Procter & Gamble Company Cleaning compositions including nuclease enzyme and malodor reduction materials
EA031933B1 (ru) * 2016-08-05 2019-03-29 Общество С Ограниченной Ответственностью "Научно-Производственный Центр Пробиотех" Ветеринарный биопрепарат, способ его получения (варианты) и способ лечения нодулярного дерматита крупного рогатого скота (варианты)
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
WO2018094253A1 (en) 2016-11-18 2018-05-24 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
WO2019183006A1 (en) * 2018-03-19 2019-09-26 Liang Gui Bai Methods and compositions for treating idiopathic pulmonary fibrosis
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
KR20210003197A (ko) 2018-04-23 2021-01-11 티엘씨 바이오파머슈티컬즈 인코포레이티드 폐 질환 치료에 사용하기 위한 흡입 가능한 리포솜 서방형 조성물
CN111249251A (zh) * 2018-12-03 2020-06-09 华中农业大学 一种恩诺沙星壳聚糖纳米粒
CA3131712A1 (en) * 2019-02-22 2020-08-27 Cila Therapeutic Inc. Inhalable therapeutic agent
CN114007590A (zh) * 2019-06-28 2022-02-01 江苏恒瑞医药股份有限公司 一种缓释脂质组合物及其制备方法
CN113018443B (zh) * 2019-12-27 2022-09-13 海南斯达制药有限公司 治疗呼吸系统疾病的药物组合物及其制备方法
CN113116823B (zh) * 2019-12-30 2024-02-20 江苏恒瑞医药股份有限公司 一种脂质体及其制备方法
CN111420024B (zh) * 2020-04-07 2023-10-03 中国科学院深圳先进技术研究院 杆菌酞a在制备预防和治疗冠状病毒的药物中的应用
CN112076193B (zh) * 2020-10-13 2021-10-26 苏州大学 甲氧喹酸在制备用于治疗和/或预防以t-型钙通道为治疗靶点的疾病的药物中的应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2000414A (en) 1932-08-10 1935-05-07 Ig Farbenindustrie Ag Explosive composition
US4142026A (en) 1977-04-22 1979-02-27 Zordan Macario J Dry cell adapter
DE2848503C2 (de) 1978-11-08 1983-05-05 Alcan Aluminiumwerk Nürnberg GmbH, 6000 Frankfurt Maschinengehäuse mit einem eine relativ geringe Wandstärke aufweisenden Bauteil
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IL83567A (en) 1986-08-18 1992-02-16 Dow Chemical Co Starburst conjugates with a carried material,such as an agricultural or pharmaceutical material
US4957998A (en) 1988-08-22 1990-09-18 Pharmaceutical Delivery Systems, Inc. Polymers containing acetal, carboxy-acetal, ortho ester and carboxyortho ester linkages
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US6623671B2 (en) 1990-10-05 2003-09-23 Royden M. Coe Liposome extrusion process
ATE132367T1 (de) 1991-02-14 1996-01-15 Baxter Int Bindung substratspezifischer affinitätssubstanzen an liposomen
US5176907A (en) 1991-08-13 1993-01-05 The Johns Hopkins University School Of Medicine Biocompatible and biodegradable poly (phosphoester-urethanes)
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6890555B1 (en) 1992-02-05 2005-05-10 Qlt, Inc. Liposome compositions of porphyrin photosensitizers
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5367051A (en) 1993-07-22 1994-11-22 Sri International Amine-containing polymerizable monomers and polymers functionalized with fullerenes to provide polymers with high temperature stability
CA2101241C (en) 1993-07-23 1998-12-22 Jonathan P. Wong Liposome-encapsulated ciprofloxacin
EP0678017B1 (en) 1993-11-05 1998-04-01 Amgen Inc. Liposome preparation and material encapsulation method
ATE277640T1 (de) 1994-03-07 2004-10-15 Dow Chemical Co Bioaktive und/oder gezielte dendrimere-konjugate enthaltend genetisches material
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
DE69632859T2 (de) * 1995-04-18 2005-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Verfahren zur Arzneistoffbehandlung von Liposomen Zusammensetzung
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US6197333B1 (en) 1996-03-28 2001-03-06 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved liposome compositions
CA2174803C (en) 1996-04-23 2000-07-11 Jonathan P. Wong Use of liposome encapsulated ciprofloxacin as an immunotherapeutic drug
GB9609779D0 (en) 1996-05-10 1996-07-17 Univ Bruxelles Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2215716C (en) 1997-09-17 1999-12-07 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Aerosol delivery of liposome-encapsulated fluoroquinolone
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
KR100445146B1 (ko) * 1998-05-27 2004-08-18 유로-셀띠끄 소시에떼 아노님 항염증용 제제, 특히 하부호흡기의 창상치료 촉진용 약제및/또는 소독 약제
JP2002520120A (ja) 1998-07-17 2002-07-09 スカイファーマ インコーポレーテッド 封入物質の制御放出のための生分解性組成物
CZ20011581A3 (cs) * 1998-11-12 2001-12-12 Frank G. Pilkiewicz Systém pro podávání bioaktivní sloučeniny inhalací
US6855296B1 (en) 1998-11-13 2005-02-15 Optime Therapeutics, Inc. Method and apparatus for liposome production
AU756196B2 (en) 1998-11-13 2003-01-09 Optime Therapeutics, Inc. Method and apparatus for liposome production
WO2001000246A2 (en) 1999-06-11 2001-01-04 Shearwater Corporation Hydrogels derived from chitosan and poly(ethylene glycol)
WO2001000173A1 (fr) * 1999-06-24 2001-01-04 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de la fuite de medicaments encapsules dans des liposomes
US6392008B1 (en) 1999-07-21 2002-05-21 The Penn State Research Foundation Polyphosphazene polymers
DE19954843C2 (de) 1999-11-09 2003-11-20 Novosom Ag Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren Verwendung
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002092661A1 (en) 2001-05-11 2002-11-21 Ap Pharma, Inc. Peg-poe, peg-poe-peg, and poe-peg-poe block copolymers
US20030224039A1 (en) 2002-03-05 2003-12-04 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
MXPA05004580A (es) 2002-10-29 2005-07-26 Transave Inc Liberacion sostenida de anti - infecciosos.
KR20060015265A (ko) * 2003-05-30 2006-02-16 알자 코포레이션 제제의 폐 투여 방법
FR2856844B1 (fr) 2003-06-24 2006-02-17 Commissariat Energie Atomique Circuit integre sur puce de hautes performances
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
AU2005207960A1 (en) 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
US8226975B2 (en) 2005-12-08 2012-07-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile

Also Published As

Publication number Publication date
EP2079443B1 (en) 2014-08-27
EP2079443A4 (en) 2012-03-07
WO2008063341A3 (en) 2008-10-16
EP2789330A1 (en) 2014-10-15
SI2079443T1 (sl) 2014-12-31
JP5797217B2 (ja) 2015-10-21
AU2007322224A1 (en) 2008-05-29
US8268347B1 (en) 2012-09-18
WO2008063341A2 (en) 2008-05-29
ES2520028T3 (es) 2014-11-11
CN101553209A (zh) 2009-10-07
CA2667494C (en) 2015-05-19
CA2667494A1 (en) 2008-05-29
EP2079443A2 (en) 2009-07-22
PT2079443E (pt) 2014-11-26
JP2013116909A (ja) 2013-06-13
JP5254239B2 (ja) 2013-08-07
DK2079443T3 (en) 2014-12-08
EP2759292A1 (en) 2014-07-30
US20120282328A1 (en) 2012-11-08
US8414915B2 (en) 2013-04-09
CN104666248A (zh) 2015-06-03
AU2007322224B2 (en) 2012-05-17
US20120244206A1 (en) 2012-09-27
JP2010507658A (ja) 2010-03-11
CN104666248B (zh) 2017-11-03

Similar Documents

Publication Publication Date Title
PL2079443T3 (pl) Podwójne działanie, wziewne formulacje zapewniające zarówno natychmiastowy jak i przedłużony profil uwalniania
GB2435419B (en) Formulations
IL194688A0 (en) Rapid acting and long acting insulin combination formulations
IL184460A0 (en) Sustained release pharmaeutical formulations
HK1200092A1 (en) Sustained release formulations
EP2046930A4 (en) FORMULATIONS BASED ON RHAMNOLIPIDS
ZA200801158B (en) Sustained drug release composition
HRP20130109T1 (en) Caspofungin formulations
EP2046290A4 (en) AQUEOUS DRONABINOL FORMULATIONS
GB0605780D0 (en) Formulations
ZA200901132B (en) Human GLP-1 mimetibodies, compositions, methods and uses
IL198168A0 (en) Robust sustained release formulations
HK1180949A1 (en) Long lasting drug formulations
EP2090300A4 (en) PREPARATION WITH EXTENDED RELEASE
GB0718409D0 (en) Formulations
GB0610336D0 (en) Formulations
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
GB0503509D0 (en) An improved delivery agent
EP2345660A4 (en) ANTI-XDR-TB-MEDIUM, ANTI-MDR-TB-MEDIUM AND COMBINED ANTIBODY CLOUD
GB0705395D0 (en) Breath deodoriser
GB0716700D0 (en) Inhaled combination theraphy
GB0718404D0 (en) Formulations
IL177596A0 (en) Inhalation formulations
GB0603380D0 (en) Formulations
GB0618691D0 (en) Formulations